



ASX & Media Release

Patrys Granted Key Patent for Lead Product – PAT-SM6

- **Issued U.S. patent for lead product PAT-SM6 providing protection through year 2024**
- **Patent covers PAT-SM6 binding to Low Density Lipoprotein (LDL) and components of LDL**

Melbourne, Australia; 24 May, 2012: Patrys Limited (ASX: PAB; "the Company"), a clinical stage biopharmaceutical company, is pleased to advise that it has just been granted a U.S. patent for lead product PAT-SM6.

PAT-SM6 is a natural human antibody that has shown promise as a potential treatment for multiple types of cancer including melanoma and multiple myeloma. In February 2012, the Company announced successful data from a Phase I clinical trial in patients with in-transit melanoma. Currently, the Company is preparing to undertake a Phase I/IIa clinical trial using PAT-SM6 in patients with relapsed and multi-resistant multiple myeloma. It is planned that this trial will commence at the University of Würzburg in the second half of 2012.

The patent granted by the U.S. Patent Office as *US 8,124,080* contains claims that cover the PAT-SM6 antibody binding to low-density lipoprotein (LDL) and components of LDL which are believed to be involved in the mode of action for the product. This is the second U.S. patent that has been granted covering the PAT-SM6 product.

Patrys' patent applications covering PAT-SM6 offer protection through to at least 2024 with the possibility of an extension of term.

Dr Marie Roskrow, Patrys' CEO said: "The success in the granting of this recent PAT-SM6 patent is an endorsement of the novelty of our products and reinforces the commercial value of Patrys' pipeline."

"This patent is a key component of our intellectual property (IP) portfolio and provides long term market exclusivity for Patrys' PAT-SM6 product for the treatment of cancer. This issued patent expands our global IP protection as we plan to take the product into a second clinical trial."

-Ends-

For further information, please contact:

Patrys Limited:

Dr. Marie Roskrow
Chief Executive Officer
P: +61 3 9670 3273
info@patrys.com

Patrys IR:

Rebecca Wilson
Buchan Consulting
P: 0417 382 391
rwilson@buchanwe.com.au

Patrys Media:

Tom Donovan
Buchan Consulting
P: +61 3 9866 4722
tdonovan@buchanwe.com.au

About Patrys Limited:

Based in Melbourne, Australia, Patrys (ASX: PAB) a clinical stage company, is focused on the development of natural human antibody therapies for cancer. More information can be found at www.patrys.com.

**About PAT-SM6:**

The natural human antibody PAT-SM6 has been shown to have potent anti-cancer properties in a large number of laboratory and animal studies. More specifically, Patrys has now screened PAT-SM6 against more than 200 tumours from individual patients with various cancers, and the product binds to over 90% of the tumours screened regardless of cancer type or patient age, gender or disease stage. With respect to melanoma, PAT-SM6 has shown particularly strong promise. Patrys has filed patent applications to cover the PAT-SM6 antibody molecule, disease target, and the mechanism of action. In October 2010, Patrys initiated a human clinical trial to evaluate PAT-SM6 as a therapy for melanoma. This trial concluded in February 2012. The clinical trial took place at the Royal Adelaide Hospital Cancer Centre and associated Pain and Anaesthesia Research Clinic and the Princess Alexandra Hospital in Queensland.

About Low-density Lipoprotein (LDL) and PAT-SM6 mechanism of killing:

LDL is one of the five major groups of lipoproteins, which in order of size, largest to smallest, are chylomicrons, VLDL, IDL, LDL, and HDL, that enable transport of multiple different fat molecules, including cholesterol, within the water around cells and within the water-based bloodstream. Lipoproteins are essential for normal and malignant cells during growth and differentiation. The natural human antibody PAT-SM6 binds to both an oxidized low-density lipoprotein and a cell surface receptor on cancer cells called GRP78. The PAT-SM6 antibody induces an excess of intracellular lipoproteins, by overfeeding malignant cells with oxidized LDL via receptor-mediated endocytosis. This in turn leads to a deadly accumulation of lipoproteins leading to apoptotic cell death. The PAT-SM6 is the first reported human monoclonal antibody to display this dual binding characteristic.